Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid FeaturesBradley A. McGregor, Toni K. Choueiri, Kathryn P. Gray et al.|Journal of Clinical Oncology|2019Cited by 147
Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancerDana E. Rathkopf, Andrew J. Armstrong, Manish R. Patel et al.|Annals of Oncology|2024Cited by 66